

ASX ANNOUNCEMENT

28 May 2024

Notice of Annual General Meeting – Withdrawal of Resolution

BRISBANE, Australia and **MINNEAPOLIS, USA**, Anteris Technologies Ltd (**Anteris** or the **Company**) (ASX: AVR) advises that the Board has resolved to withdraw Resolution 3 (Approval of 10% Placement Facility) from the agenda of the Company's Annual General Meeting of shareholders scheduled to take place at 10:00 am (AEST) on Wednesday 29 May 2024 (2024 AGM).

Resolution 3 requested the approval of shareholders to increase the number of shares the Company is able to issue without shareholder approval over the 12-month period on and from the date of the 2024 AGM by up to 10% of the issued capital of the Company at the time of issue, under ASX Listing Rule 7.1A.

The Board has resolved to withdraw Resolution 3 because, as at the close of trading on the date of this announcement, the Company is no longer an "eligible entity" within the meaning of the ASX Listing Rules on account of the Company's market capitalisation exceeding \$300 million, and therefore shareholder approval of additional placement capacity under ASX Listing Rule 7.1A is not available to the Company.

The withdrawal of Resolution 3 will not affect the validity of the proxy form provided in connection with the 2024 AGM or any proxy votes already submitted in respect of the remaining resolutions to be put to shareholders for approval at the 2024 AGM.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

REGISTERED OFFICE

Toowong Tower, Level 3, Suite 302
9 Sherwood Road
Toowong, QLD 4066
Australia



BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

T: +61 1300 550 310
info.au@anteristech.com
anteristech.com

Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
Twitter	@AnterisTech
Facebook	www.facebook.com/AnterisTechnologies
LinkedIn	https://www.linkedin.com/company/anteristech

